Qurient큐리언트

Qurient remains deeply loss-making, with heavy borrowings and a rights offering underway, though it is advancing its cancer drug pipeline and a Lonza partnership.

Qurient is a Korean drug developer with a small revenue base of about ₩7.1B over the last twelve months and an operating loss of about ₩36.8B. Its cash of about ₩2.3B is far below borrowings of about ₩9.5B, and the company is currently running a rights offering that adds new shares. The share price has fallen 13.8% over one month and is roughly 69% below its 52-week high.

What stands out

• Trailing revenue of about ₩7.1B is small against an operating loss of about ₩36.8B, a -520.5% operating margin.
• Revenue fell 23.9% in 2025 to about ₩7.0B, and losses have been large every year since 2021.
• Free cash flow over the trailing period was about -₩32.4B, and liabilities are 109% of equity.
• Recent headlines centre on a dual-payload ADC platform with Lonza and Phase 1 data for mocaciclib presented at ESMO, though the data does not show any revenue from these deals.
• Foreign ownership fell from 6.4% to 2.7% over about 60 days, and foreign and institutional investors were net sellers over the last 20 days.

What to watch

• Terms and completion of the rights offering, including the issue price and how much new share capital it adds, as listed in recent filings.
• Whether the Lonza partnership or planned third-party technology transfers lead to disclosed payments or revenue.
• Continued cash burn against cash of about ₩2.3B and borrowings of about ₩9.5B, as the next financial results are filed.